Management of INR 1.9 with Target 2.5
For a single INR of 1.9 with a target of 2.5 (therapeutic range 2.0-3.0), continue your current warfarin dose without adjustment and recheck the INR in 1-2 weeks. 1
Rationale for No Dose Change
The ACCP guidelines explicitly address this scenario: when patients on stable warfarin therapy present with a single out-of-range INR within 0.5 of the therapeutic target, the evidence supports continuing the current dose rather than making adjustments 1. Your INR of 1.9 is only 0.1 below the lower limit of 2.0, well within this guideline recommendation.
Supporting Evidence
An RCT directly compared one-time dose adjustments versus no change for INRs between 1.5-4.4 in stable patients. No significant difference was found in achieving therapeutic range at 2-week follow-up (44% out-of-range with dose change vs 40% with no change; OR 1.17,95% CI 0.59-2.30) 1, 2. A more recent 2022 study analyzing 45,351 slightly out-of-range INRs confirmed these findings, showing only a 1.1% absolute difference between watchful waiting and dose changes—statistically significant but clinically negligible 3.
Key Clinical Points
- This applies to isolated, single INR values in previously stable patients
- An observational model of 3,961 patients suggested warfarin doses don't require adjustment for INRs between 1.7-3.3 1
- No major bleeding or thromboembolic events occurred in studies using this approach 1, 2
Important Caveats
Do NOT follow this approach if:
- You have multiple consecutive subtherapeutic INRs (not just one isolated value)
- There are new medications, dietary changes, or illness affecting warfarin metabolism
- The patient has a mechanical heart valve (higher thrombotic risk)
- This is a new patient without established stability on warfarin
Monitoring Plan
- Recheck INR in 1-2 weeks 1
- If the repeat INR remains subtherapeutic or shows a downward trend, then adjust the weekly warfarin dose by 5-20% 4
- More frequent monitoring (2-4 times weekly) is only needed if you make dose adjustments 4
Bridging Consideration
Do not bridge with heparin or LMWH for this single subtherapeutic INR. Studies show no significant difference in thromboembolic events between patients with isolated low INRs versus those with therapeutic INRs (0.3% event rate, 95% CI 0-1.9%) 1. Bridging is not routinely indicated unless there are multiple consecutive subtherapeutic values or very high thrombotic risk.
Target INR Confirmation
The FDA label and ACCP guidelines confirm that for most indications (atrial fibrillation, VTE, etc.), the target INR should be 2.5 with a therapeutic range of 2.0-3.0 5, 6. While one recent study from Asia suggested a lower target of 1.5-2.5 may reduce bleeding 7, this contradicts established international guidelines and the robust evidence base supporting 2.0-3.0 5. The 2018 CHEST guidelines explicitly state there is "no robust evidence" for lower INR targets and recommend the conventional 2.0-3.0 range globally 5.